目的：探讨含吡嗪酰胺（PZA）抗结核方案与肺结核并乙肝患者药物性肝损伤的相关性，为临床优化治疗方案提供依据。方法：选取2013年1月至2014年12月我院诊治的初治肺结核并HBV-DNA 阳性199例为观察组，103例无合并症初治肺结核为对照组。观察组中抗结核联合抗病毒122例，64例予HRZE方案（A组），58例予HRE方案（B组）；抗结核未联合抗病毒77例，41例予HRZE 方案（C组），36例予HRE方案（D组）；对照组103例予HRZE方案（E组）。2个月后观察各组肝损伤情况。结果：（1）A组肝损伤发生率为34．38％，高于 B 组的20．69％（P ＞0．05）；（2） C 组肝损伤发生率显著高于 D 组（73．17％ vs．30．56％）（P ＜0．05）。（3）B组较D组肝损伤发生率低（20．69％ vs．30．56％）（P ＞0．05）。（4）A组较C组的肝损伤发生率低（34．38％ vs．73．17％）（P ＜0．05）；（5）A 组较 E 组肝损伤发生率高（34．38％ vs．17．48％）（P ＜0．05）；B组与E组肝损伤发生率相近（20．69％ vs．17．48％）（P ＞0．05）。结论：PZA对肺结核并HBV-DNA 阳性患者抗结核治疗的肝损伤发生率及肝损伤的严重程度有较大影响，联合抗病毒治疗对预防该类患者肝损伤发生率及减轻肝损伤的严重程度可起一定的作用，但不能最大程度避免肝损伤的发生，临床上应权衡利弊，必要时更改使用含PZA的治疗方案，以减少肝损伤发生。%Objective To study the correlation of PAZ with anti-tuberculosis treatment regimen and drug-induced liver injury in tuberculosis patients with HBV-DNA positive in order to provide an optimized treatment regimen. Methods from Jan 2013 to Dec 2014, 199 pulmonary tuberculosis with HBV-DNA positive patients and 103 pulmonary tuberculosis patients without HBV in our hospital were collected. They were assigned as follows:122 cases were anti tuberculosis treatment with antiviral therapy,64 cases were A(HRZE),58 cases were B (HRE). 77 cases were anti tuberculosis treatment but not antiviral therapy , 41 cases were C (HRZE), 36 cases were D(HRE) and 103 patients without HBV were E (HRZE, the contrast group). We had observed the liver injury for 2 months after the treatment. Results 1.Incidence of liver injury was 34.38% in group A , higher than the cases in group B(20.69%,P > 0.05). 2.Incidence of liver injury in group C was apparently higher than in group D (73.17% vs. 30.56%,P < 0.05). 3.Incidence of liver injury in group B was lower than group D (20.69% vs. 30.56%,P > 0.05)4.Incidence of liver injury in group A was lower than group C (34.38% vs. 73.17%,P < 0.05).5. Incidence of liver injury in group A was higher than group E (34.38% vs. 17.48%,P< 0.05)and there was no difference between group B and group E (20.69% vs. 17.48%,P> 0.05). Conclusion Although anti tuberculosis treatment combined with antiviral therapy can be partially reduce the incidence of liver injury and relieve the severity of liver injury in tuberculosis patients infected with HBV , but PZA toxicity to hepatocytes is a major risk factor for liver injury , and we need to change the treatment plan to reduce the occurrence of liver injury.
展开▼
